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Abstract 
Magnetic nanoparticles (MNPs) have been extensively used as contrasts and tracers for bioimaging, heating 
sources for tumor therapy, carriers for controlled drug delivery, and labels for magnetic immunoassays. Here, we 
describe a MNP Brownian relaxation dynamics-based magnetic particle spectroscopy (MPS) method for the 
quantitative detection of molecular biomarkers. In MPS measurements, the harmonics of oscillating MNPs are 
recorded and used as a metric for the freedom of rotational motion, which indicates the bound states of the MNPs. 
These harmonics can be collected from microgram quantities of iron oxide nanoparticles within 10 seconds. Since 
the harmonics are largely dependent on the quantity of the MNPs in the sample, the MPS bioassay results could 
be biased by the deviations of MNP quantities in each sample, especially for the very low concentration biomarker 
detection scenarios. Herein, we report three MNP concentration/quantity-independent metrics for characterizing 
the bound states of MNPs in MPS. Using a streptavidin-biotin binding system as a model, we demonstrate the 
feasibility of using MPS and MNP concentration/quantity-independent metrics to sense these molecular 
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interactions, showing this method can achieve rapid, wash-free bioassays, and is suitable for future point-of-care 
(POC), sensitive, and versatile diagnosis. 
Keywords: magnetic nanoparticle, magnetic particle spectroscopy, Brownian relaxation, wash-free, point-of-
care, bioassay 
 
1. Introduction 
In recent years, magnetic nanoparticles (MNPs) have been successfully applied as nano-heaters for hyperthermia 
therapy, nano-carriers for drug delivery, nano-tracers for magnetic particle imaging (MPI), nano-contrast agents 
for magnetic resonance imaging (MRI), and nano-labels for magnetic bioassays.1–27 MNPs, with physical size 
comparable to biologically important substances, have many unique physicochemical properties such as high 
surface to volume ratio and size-dependent magnetic properties, making them ideal for many novel applications. 
Nowadays, MNPs with a properly functionalized surface can be physically and chemically stable, biocompatible, 
and environmentally-friendly.28 Furthermore, biological samples exhibit virtually no magnetic background, thus 
high sensitivity measurements can be performed on minimally processed samples in MNP-based biomedical 
applications. In addition, the ease of synthesis and facile surface chemistry have generated much eagerness in 
applying MNPs to clinical diagnostics and therapy. 
    Magnetic particle spectroscopy (MPS) is a novel measurement method that closely relates to MPI, which has 
been widely explored by many groups in recent years.29–41 In MPS, sinusoidal magnetic fields periodically drive 
MNPs into magnetically saturated regions which generate magnetic responses that contain not only the drive field 
frequencies but also a series of harmonic frequencies. These harmonic components can be easily extracted by 
means of filtering and fast Fourier transform (FFT). The harmonics are very useful metrics of the MNP ferrofluids 
which contain important information such as the viscosity and temperature of MNP solution as well as the 
conjugation of any ligands/chemicals onto MNPs.30,42–50 It has been reported that since the harmonic amplitude 
is largely dependent on the quantity of the MNPs in the sample, the MPS bioassay results could be biased by the 
deviations of MNP quantities in each sample, especially for the very low concentration biomarker detection 
scenarios.30,30,34 Due to this concern, it has been reported that magnetic susceptibility is MNP quantity-
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independent for MNP-based immunoassays.51–53 Herein, we are reporting three MNP concentration/quantity-
independent metrics for characterizing the bound states of MNPs in MPS, namely, the  𝑓𝑓𝐻𝐻,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 at peak harmonic 
amplitude (unit: Hz), ½FWHM (unit: Hz), and the ratios of the 3rd to the 5th harmonics (R35). We used a MNP 
Brownian relaxation dynamics-based MPS method as the model for the rapid and wash-free molecular sensing. 
This type of measurement relies on the fact that the tendency of MNPs’ magnetic moments to align with the 
external magnetic field is countered by the Brownian relaxation that randomizes the MNPs’ alignment. The extent 
of disorder caused by Brownian relaxation is most sensitive to the bound state of MNPs, namely, the 
hydrodynamic size. The higher harmonics (the 3rd and 5th harmonics) are extracted from the MPS for analyzing 
the bound states of MNPs.  
We verified the feasibility of using these MNP concentration/quantity-independent metrics in MNP Brownian 
relaxation-based MPS molecular sensing. The well-characterized streptavidin and biotin system with ultra-high 
binding affinity is chosen as the model system, demonstrating the validity of MPS and MNP 
concentration/quantity-independent metrics for future rapid, point-of-care (POC), sensitive, and versatile 
immunoassays. The results show that MNP Brownian relaxation-based MPS method can detect analytes directly 
from biological samples with minimum sample preparation in a wash-free manner. 
 
2. Materials and Methods 
    Material. The MNPs used in this work are iron oxide nanoparticles (IONPs) with average core size of 30 nm 
and coated with a layer of biotin, purchased from Ocean NanoTech, San Diego, California (catalog no. SHB-30). 
The streptavidin from Streptomyces avidinii is a salt-free, lyophilized powder with biotin binding capacity of 13 
units/mg protein, purchased from Sigma-Aldrich inc., Atlanta, Georgia (product no. S4762). Phosphate buffered 
saline (PBS) is purchased from Sigma-Aldrich inc., Atlanta, Georgia (product no. 79378). 
Sample Preparation. The lyophilized streptavidin powder is reconstituted in PBS and prepared with different 
concentrations vary from 75 nM to 15 µM. As shown in Scheme 1, six samples (vial I - VI) are prepared and each 
sample contains approximately 100 µL MNPs. Vials I - V are active groups and each vial is added with 100 µL 
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streptavidin of different concentrations. Vial VI serves as control group and it is added with 100 µL PBS. All the 
samples are mixed well and incubated at room temperature for 30 minutes to allow the binding of streptavidin to 
biotins from MNPs.  
Scheme 1. Composition of six MNP samples. 
 
    Conjugation of Streptavidin to MNPs. Streptavidin is a crystalline tetrameric protein, with a molecular 
weight of 4 × 15 kDa, it binds four molecules of biotin and has a high binding affinity to biotin ligands 
(dissociation constant 𝐾𝐾𝑑𝑑 = 10−14 𝑀𝑀). The binding between biotin and streptavidin is very fast, and once formed, 
it is independent of temperature, solvents, pH, and other denaturing agents. Each streptavidin hosts 4 biotin 
binding sites, which allows the interaction with multiple biotin moieties from different MNPs and, as a result, 
forms MNP clusters. 
    Experimental Setups. The MPS measurement system setups and signal chain are shown in Figure 1(a) & (b). 
A personal computer (PC) controls the data acquisition card (DAQ, NI USB-6289) to generate two sinusoidal 
signals, which are amplified by two instrument amplifiers (IA, HP 6824A), followed by two band pass filters 
(BPFs) to suppress higher harmonics that might be introduced by IAs. These amplified and filtered sinusoidal 
signals drive the outer and inner coils (see Figure 1(c) & (d)) to generate oscillating magnetic fields: one with 
frequency 𝑓𝑓𝐿𝐿 = 10 𝐻𝐻𝐻𝐻 and amplitude 𝐴𝐴𝐿𝐿 = 170 𝑂𝑂𝑂𝑂, the other with frequency 𝑓𝑓𝐻𝐻 varies from 500 Hz to 20 kHz 
and amplitude 𝐴𝐴𝐻𝐻 = 17 𝑂𝑂𝑂𝑂. One pair of differentially wound pick-up coils (600 windings in clock-wise and 600 
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windings in counter-clock-wise) collect the induced voltage and phase signals from MNPs and send back to a 
BPF before digitalized on the DAQ. The response signals at combinatorial frequencies 𝑓𝑓𝐻𝐻 ± 2𝑓𝑓𝐿𝐿 (3rd harmonic) 
and 𝑓𝑓𝐻𝐻 ± 4𝑓𝑓𝐿𝐿 (5th harmonic) are analyzed. 
 
Figure 1. MPS measurement system setups. (a) Photograph of system setups. (b) Signal chain. The system used 
in this work records nonlinear magnetic response of MNPs under two oscillating magnetic fields with frequencies 
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of 𝑓𝑓𝐻𝐻 and 𝑓𝑓𝐿𝐿. (c) Photograph of coils: (i) low frequency drive coil (outer coil); (ii) high frequency drive coil (inner 
coil); (iii) a pair of pick-up coils; (iv) plastic vial with a capacity of 300 µL. (d) Photograph of assembled coils. 
 
Molecular Sensing via MPS. When the single domain MNPs are suspended in solution and subjected to an 
external magnetic field, there are two mechanisms by which the magnetic moments rotate in response to the 
magnetic field (see Scheme 2(a) & (b)): the intrinsic Néel motion (rotating magnetic moment inside a stationary 
particle) and the extrinsic Brownian motion (rotating the entire particle along with its magnetic moment). In 
principle, both the Néel and Brownian mechanism play a role in determining the magnetization of MNP 
ferrofluids subjected to external oscillating magnetic fields.32 In this work, we use MNPs with core size of 30 nm, 
where the Brownian mechanism is dominant and the Néel mechanism is minimized. For these Brownian-
relaxation-dominated MNPs, their MPS responses are most sensitive to the hydrodynamic sizes of MNPs. As 
shown in Scheme 2(c) & (d), when the target biomarker (i.e., streptavidin) has multiple binding sites, ligands (i.e., 
biotins) from more than one MNP can bind to the same biomarker, resulting in the clustering of MNPs. Such an 
interaction greatly increases the hydrodynamic sizes of MNPs as well as the Brownian relaxation time. As a result, 
noticeable changes could be found from the MPS responses due to this specific binding process. Mathematical 
models of the relaxation mechanisms can be found in Notes S1 & S2 in the Supporting Information. 
 
Scheme 2. (a) Néel relaxation is the rotation of magnetic moment inside a stationary MNP. (b) Brownian 
relaxation is the rotation of entire MNP along with the magnetic moment. (c) The streptavidin has a high binding 
affinity to the biotin ligands on MNP surface. (d) As the quantity of streptavidin increases in the MNP suspension, 
the MNPs are likely to form clusters. The dashed lines represent the hydrodynamic sizes of MNPs due to the 
clustering induced by streptavidin. As the MNP clustering level increases, the hydrodynamic size increases, and 
the harmonic amplitude decreases. 
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3. Results and Discussions 
    MPS Characterization of Magnetic Relaxation Dynamics. The MPS response upon increasing streptavidin 
concentrations from 75 nM to 15 µM is investigated, and one control group is added in this experiment to verify 
this detection strategy: biotin coated MNPs with the addition of PBS. The frequency of high frequency drive field 
𝑓𝑓𝐻𝐻 is varied at 500 Hz, 1 kHz, 2 kHz, 4 kHz, 6 kHz, 8 kHz, 10 kHz, 12 kHz, 14 kHz, 16 kHz, 18 kHz, and 20 
kHz, and the frequency of the low frequency drive field 𝑓𝑓𝐿𝐿 is set at 10 Hz. The amplitudes of both high and low 
frequency drive fields are identical in each test. During each test, the background noise is monitored for 10 s, then 
the plastic vial containing 200 µL sample is inserted into the pick-up coils and followed by another 10 s of data 
collection on the total signal. Some examples of the real-time magnetic responses sensed by pick-up coils are 
shown in Note S8 in the Supporting Information. The MPS response of MNPs is extracted by subtracting the 
background noise from the total signal using the phasor theory we reported before:37,54,55 
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𝐴𝐴𝑀𝑀𝑀𝑀𝑀𝑀𝑂𝑂
𝑗𝑗𝜑𝜑𝑀𝑀𝑀𝑀𝑀𝑀�
𝑚𝑚
= 𝐴𝐴𝑇𝑇𝑇𝑇𝑇𝑇𝑂𝑂𝑗𝑗𝜑𝜑𝑇𝑇𝑇𝑇𝑇𝑇�𝑚𝑚 − 𝐴𝐴𝑀𝑀𝑁𝑁𝑐𝑐𝑁𝑁𝑁𝑁𝑂𝑂𝑗𝑗𝜑𝜑𝑀𝑀𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁�𝑚𝑚 (1), 
Where 𝐴𝐴𝑀𝑀𝑀𝑀𝑀𝑀, 𝐴𝐴𝑇𝑇𝑇𝑇𝑇𝑇, 𝐴𝐴𝑀𝑀𝑁𝑁𝑐𝑐𝑁𝑁𝑁𝑁 are the amplitudes from MNPs, total signal, and the background noise, respectively, 
and 𝜑𝜑𝑀𝑀𝑀𝑀𝑀𝑀 , 𝜑𝜑𝑇𝑇𝑇𝑇𝑇𝑇 , and 𝜑𝜑𝑀𝑀𝑁𝑁𝑐𝑐𝑁𝑁𝑁𝑁  are the phase angles from MNPs, total signal, and the background noise, 
respectively, 𝑚𝑚 represents the mth measured harmonic. Phasor model can be found in Note S4 in the Supporting 
Information. 
 
Figure 2. (a, c) MPS measurements of the 3rd and 5th harmonics from six MNP samples in different bound states. 
Error bar represents standard deviation. (b, d) MPS measurements of the normalized 3rd and 5th harmonics from 
six MNP samples in different bound states. The insets in (b) & (d) highlight the normalized harmonic amplitudes 
measured at 500 Hz and 10 kHz, respectively. Dotted line represents the position of peak harmonic signal for 
each sample as the drive field frequency varies. 
 
The 3rd and 5th harmonic amplitudes of MNPs from six samples are reconstructed from the total signals and 
background noise, they are summarized in Figure 2(a) & (c). According to the Debye model and Faraday’s law 
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of induction (mathematical models of the MPS responses can be found in Notes S3 - S5 in the Supporting 
Information), the harmonic amplitude is dependent on the drive field frequency 𝑓𝑓𝐻𝐻, the cosine of phase lag 𝜑𝜑, and 
the quantity of MNPs in the testing sample. The increased streptavidin concentration/quantity in the MNP sample 
causes larger MNP clusters, thus, the hydrodynamic size of MNPs increases and the phase lag increases, which, 
as a result, causes noticeable drop in harmonic amplitudes (see Scheme 2(d)). As shown in Figure 2(a) & (c), the 
harmonic amplitudes of the 3rd and 5th harmonics decreases as we increase the concentration/quantity of 
streptavidin in the MNP sample. However, the harmonic amplitudes from vial V (75 nM) are larger than those of 
the control sample. Which is due to the deviations of MNP quantities in each sample. Since the harmonic 
amplitude is largely dependent on the quantity of the MNPs from the sample, the testing results could be biased 
by the deviations of MNP quantities in each sample, especially for the very low concentration biomarker detection 
scenarios. Thus, in this paper, we used the MNP quantity-independent metrics: the normalized 3rd and 5th 
harmonics and the ratios of the 3rd to the 5th harmonics (R35) to quantify the concentrations of target biomarker.  
Firstly, we report here the normalized 3rd and 5th harmonics as a MNP quantity-independent metric for 
biomarker detection, which are plotted in Figure 2(b) & (d). The dotted lines represent the critical frequencies 
𝑓𝑓𝐻𝐻,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 where the harmonic amplitudes reach to peaks for six MNP samples. There is a clear trend that the peaks 
move to lower 𝑓𝑓𝐻𝐻 for samples with higher concentrations/quantities of streptavidin (explained in Note S9 in the 
Supporting Information). As is summarized in Table I, the 𝑓𝑓𝐻𝐻,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 at peak harmonic amplitude decreases as the 
biomarker concentrations/quantities increase. 
    The insets in Figure 2(b) & (d) highlight the normalized 3rd and 5th harmonic amplitudes measured at 500 Hz 
and 10 kHz, respectively. We compared the normalized amplitude values from six MNP samples before and after 
the onset of the peaks. It is found that before the onset of peaks (at 500 Hz), the measured normalized harmonic 
amplitudes arranged from highest to lowest are: I (15 µM) > II (7.5 µM) > III (3.8 µM) > IV (1.5 µM) > V (75 
nM) > VI (control, 0 nM). However, after the onset of peaks (at 10 kHz), the measured normalized harmonic 
amplitudes reversed, namely, from highest to lowest are: VI (control, 0 nM) > V (75 nM) > IV (1.5 µM) > III (3.8 
µM) > II (7.5 µM) > I (15 µM), which indicates that the peak widths from the normalized 3rd and 5th harmonic 
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curves vary for six MNP samples in different bound states. In view of this, we introduce the full width at half 
maximum (FWHM) as another MNP quantity-independent metric for characterizing the biomarker 
concentrations/quantities from MNP samples. Since the normalized harmonic amplitude curves in Figure 2(b) & 
(d) are not full pulse waveforms, we use ½FWHM, which is the difference between 𝑓𝑓𝐻𝐻,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 at peak harmonic 
amplitude and 𝑓𝑓𝐻𝐻,50% at 50% of the peak harmonic amplitude. It is observed from Figure 2(b) & (d) that the 
½FWHM decreases as the concentrations/quantities of streptavidin increases in the MNP sample. In other words, 
the normalized harmonic amplitude curve is steeper from MNP samples with higher concentrations/quantities of 
biomarkers. As is summarized in Table I, the ½FWHM value increases as the biomarker concentrations/quantities 
increases. 
As per best knowledge, it is for the first time that  𝒇𝒇𝑯𝑯,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 at peak harmonic amplitude and ½FWHM as MNP 
quantity-independent metrics are being used for characterizing the biomarker concentrations/quantities. 
 
Table I. Summarized peak shift of harmonic signals and ½FWHM from six MNP samples 
Vial # I 
(15 µM) 
II 
(7.5 µM) 
III 
(3.8 µM) 
IV 
(1.5 µM) 
V 
(75 nM) 
VI 
(0 nM) 
𝒇𝒇𝑯𝑯,𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 at peak harmonic 
amplitude (Hz) 
2000 2500 2700 2800 2850 2900 
½FWHM* (Hz) 11,300 11,800 12,300 12,700 12,900 13,100 
*½FWHM is the difference between 𝑓𝑓𝐻𝐻,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 at peak harmonic amplitude and 𝑓𝑓𝐻𝐻,50% at 50% of the peak harmonic 
amplitude. 
 
On the other hand, the ratios of the 3rd to the 5th harmonics (R35) at different drive field frequencies have also 
been used as a MNP quantity-independent metric for characterizing the biomarker concentrations/quantities from 
samples (the harmonic ratio model can be found in Note S6 in the Supporting Information). Figure 3(a) 
summarizes the harmonic ratios, R35, from six samples as we vary the drive field frequency 𝑓𝑓𝐻𝐻 from 500 Hz to 
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20 kHz. The harmonic ratios R35 increases as the concentrations/quantities of streptavidin increases. The inset 
figure in Figure 3(a) lists the harmonic ratios R35 from six samples at a drive field frequency of 𝑓𝑓𝐻𝐻 = 10 𝑘𝑘𝐻𝐻𝐻𝐻. 
The R35 drops from 1.7978 for sample I (streptavidin concentrations: 15 µM) to 1.4332 for sample VI 
(streptavidin concentrations: 0 nM). Figure 3(b) – (e) show the relationships between R35 and streptavidin 
concentrations under different drive field frequencies. It is noted that the harmonic ratio R35 increases as the 
concentrations/quantities of streptavidin increases in the MNP sample. Under low drive field frequency, 𝑓𝑓𝐻𝐻 =500 𝐻𝐻𝐻𝐻 (Figure 3(b)), the difference in R35 between sample I (streptavidin concentrations: 15 µM) and VI 
(streptavidin concentrations: 0 nM) is only 6%. On the other hand, under high drive field frequency, 𝑓𝑓𝐻𝐻 = 18 𝑘𝑘𝐻𝐻𝐻𝐻 
(Figure 3(e)), this difference reaches to 28%. Hence, the harmonic ratio, R35, under higher drive field frequency 
allows for better resolutions in characterizing the target biomarker concentrations. 
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Figure 3. MPS measurements of the ratio of the 3rd to the 5th harmonics (R35) of six MNP samples in different 
bound states. (a) The harmonic ratios, R35, from six samples as we vary the 𝑓𝑓𝐻𝐻 from 500 Hz to 20 kHz. The inset 
figure summarizes the R35 under a drive field frequency of 𝑓𝑓𝐻𝐻 = 10 𝑘𝑘𝐻𝐻𝐻𝐻 for vials I – VI, the R35 values are: 
1.7978 (15 µM), 1.6210 (7.5 µM), 1.4786 (3.8 µM), 1.4544 (1.5 µM), 1.4434 (75 nM), and 1.4332 (control, 0 
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nM), respectively. (b) – (d) show the relationships between R35 and streptavidin concentrations at drive field 
frequencies of (b) 500 Hz; (c) 6 kHz; (d) 12 kHz; and (e) 18 kHz. 
 
 Besides the peak shift, ½FWHM, and harmonic ratio (R35) methods, the harmonic angle is also a MNP 
concentration/quantity-independent metric for characterizing the bound states of MNPs in MPS.46 The 3rd and the 
5th harmonic angles are reconstructed from the total signals and background noise, they are summarized in Note 
S7 in the Supporting Information. 
 
    Morphological Characterization of MNPs in Different Bound States. Transmission electron microscopy 
(TEM) images are taken to investigate the MNP clusters and bound states in six samples after the MPS 
measurements. A droplet of the MNP solution (~ 10 µL) is dipped onto a TEM grid (copper mesh with amorphous 
carbon film) with filter paper underneath. The MNP droplet forms a thin liquid layer on the TEM grid and will 
be ready for TEM characterization when the solution evaporates. Then the TEM grids are characterized in TEM 
(FEI Tecnai T12, 120 kV). Well-dispersed MNPs are observed from the control sample without streptavidin (vial 
VI, 0 nM) as seen in Figure 4 (i) & (k) while more MNP clusters could be found with the increase of streptavidin 
concentrations. As shown in Figure 4 (e) - (i), increased streptavidin concentration produces larger MNP clusters 
as observed in TEM images. Figure 4 (a) shows different bound states of MNPs in the presence of streptavidin. 
Since there are multiple biotins on each MNP and the tetrameric structure of streptavidin hosting 4 biotin bindings 
sites, MNPs could form clusters, chains, tetramers, trimers, dimers, etc. Figure 4 (b) - (d) show the corresponding 
models of MNP bound states from Figure 4 (a). Figure 4 (j) & (k) are the zoomed in views of one “כ-shape” MNP 
cluster from vial I and the well-dispersed MNPs from vial VI. 
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Figure 4. Bright-field TEM images of six MNP samples in different bound states. (a) the sample I (15 µM) 
showing different MNP bound states. (b) MNP cluster model representing the blue dashed contour in (a). (c) 
MNP chain model representing the orange dotted contour in (a). (d) MNP tetramer model representing the red 
solid contour in (a). Blue square represents streptavidin, orange dot represents biotin, and grey circle represents 
MNP. (e-i) samples I (15 µM), II (7.5 µM), III (3.8 µM), V (75 nM), and VI (0 nM) showing the cluster size 
increases with the number of streptavidin increases. (j, k) comparison of sample I (15 µM) and VI (0 nM) showing 
one of the MNP clusters in the presence of streptavidin and the well dispersed MNPs in the absence of streptavidin. 
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    Hydrodynamic Size Analysis of MNPs in Different Bound States. Dynamic light scattering (DLS) 
measurements confirmed the streptavidin-specific clustering and the hydrodynamic size increased with 
streptavidin concentration. Statistic results from Figure 5 give us the mean hydrodynamic sizes of vials I - VI: 
706, 102.8, 63.2, 58.8, 58.4, and 58.3 nm, respectively. The results from DLS are in good agreement with our 
MPS and TEM measurements. 
 
Figure 5. Statistical hydrodynamic size distribution collected using DLS. (a) - (f) are vials I - VI. Solid black lines 
are cumulative distribution curves, µ and σ denote the mean and the standard deviation of hydrodynamic sizes. 
 
4. Conclusions and Future Perspectives 
In this work, we have demonstrated the feasibility of using MNP relaxation dynamics-based MPS method for 
bioassay applications. The specific binding of target analytes onto MNP surface inhibits their rotational freedom, 
thus, changes the MPS pattern. The streptavidin and biotin system are applied in this study as a model system. 
Each streptavidin has binding sites for multiple MNPs and forms MNP clusters that tremendously increase the 
hydrodynamic sizes of MNPs, as a result, noticeable changes could be found in the harmonic phase lags and 
amplitudes. Herein, we have reported three MNP concentration/quantity-independent metrics for characterizing 
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the bound states of MNPs in MPS, namely, the  𝑓𝑓𝐻𝐻,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 at peak harmonic amplitude (unit: Hz), ½FWHM (unit: 
Hz), and the ratios of the 3rd to the 5th harmonics (R35). The 𝑓𝑓𝐻𝐻,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 at peak harmonic amplitude and ½FWHM 
metrics require the full screening of drive field frequency 𝑓𝑓𝐻𝐻 from several hundred Hz to several tens’ kHz (in 
this work we varied 𝑓𝑓𝐻𝐻 from 500 Hz to 20 kHz). Although it is time-consuming to collect the MPS responses 
under varying drive field frequencies, 𝑓𝑓𝐻𝐻,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 and ½FWHM metrics can provide high sensitivity bioassays if  𝑓𝑓𝐻𝐻 
is varied with a small step width (i.e., better frequency resolution). On the other hand, the harmonic ratio R35 
provides an alternative way to carry out faster MPS bioassay measurements since it does not require the full 
screening of the drive field frequencies. As shown in Figure 3(b) – (e), it is possible to collect the R35 under one 
drive field frequency and use this metric to characterize the target biomarker concentration/quantity. However, 
the harmonic ratio R35 is unable to provide very high sensitivity bioassays compared to 𝑓𝑓𝐻𝐻,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 and ½FWHM 
metrics due to the factor that R35 from MNP samples with very low biomarker concentrations are very close to 
the control sample and it is susceptible to the system noise from MPS and the environmental noise. Although 
these subtle differences in the R35 from MNP samples with very low biomarker concentrations might be ruined 
by the noise, it’s possible to avoid this issue by using a higher accuracy MPS system with lower system noise and 
carrying out the measurements in a magnetic shielding room. In addition, it is worthwhile to mention that all the 
three MNP concentration/quantity-independent metrics we reported in this work are temperature-dependent. Thus, 
the MPS measurements should be carried out under the same testing temperature to reduce the variances between 
different MPS-based bioassays. 
    The MNP concentration/quantity-independent metrics used in this work achieved a sensitivity of 75 nM for the 
detection of streptavidin using our MPS system (7.5 pmole streptavidin). There are several advantages in this 
MPS method: wash-free and easy-to-use bioassay (measurements could be carried out on minimally processed 
biological samples by non-technicians with minimum training requirements), rapid (the testing time is within 10 
seconds), cheap (the cost for each trail only requires microgram quantities of iron oxide nanoparticles), and 
portable (the coils, amplifiers, filters, and DAQ could be assembled onto a single PCB board).  
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    Future development in this MNP relaxation dynamics-based bioassay method is to improve the sensitivity of 
MPS measurements as well as increase the signal-to-noise ratio (SNR). In summary, this MNP relaxation 
dynamics-based MPS method for bioassay applications opens a door for future point-of-care, versatile, sensitive, 
rapid, and wash-free molecular sensing.  
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